Biocon, Mylam get approval for biosimilar of cancer drug Herceptin

26-11-2013 LivemintComments (0)

BioconBiosimilarsHerceptinMylan LaboratoriesOncology

The biosimilar trastuzumab, a biological copy of Herceptin, was developed jointly by Biocon and US generic drug maker Mylan Inc., and will be sold in India under the brand name Canmab, Biocon said in a statement on Tuesday. It will be available in ...

Read more on Livemint

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top